The first treatment for macular telangiectasia type 2 is set to enter the market following U.S. FDA approval of NT-501 (revakinagene taroretcel) from Neurotech Pharmaceuticals Inc., a privately held company that has been quietly advancing its encapsulated cell therapy platform for more than two decades. Read More
A new multi-omics approach to unpicking how noncoding gene variants influence the development of common chronic diseases has identified tens of thousands of instances where variants have an impact on gene expression levels and gene splicing, the post-transcriptional modification that allows one gene to code for multiple proteins. Read More
Insilico Medicine founder and CEO Alex Zhavoronkov told BioWorld that he tries to spend as much time as possible in China, because that's where the artificial intelligence (AI) drug development company conducts synthesis and tests for early stage discovery. “And nowadays, not a day goes by without somebody launching an AI drug discovery company,” he said, noting that Chinese AI company Deepseek could be a huge disrupter. Read More
Astellas Pharma Inc. is setting up a joint venture with Yaskawa Electric Corp. to develop a new cell production platform using Yaskawa’s dual-arm humanoid robot called Maholo. Read More
Investigators at Pennsylvania State University have described a novel approach to combat Clostridioides difficile infection using a synthetic microbiome therapy, which offers an alternative to antibiotics and fecal microbiota transplant (FMT). C. diff, the main cause of antibiotic-related diarrhea, is responsible for an estimated half a million infections annually in the U.S. Read More
Martin Makary, President Donald Trump’s pick to head the U.S. FDA, took his turn before the Senate Health, Education, Labor and Pensions (HELP) Committee March 6, a week ahead of the committee’s confirmation votes on both him and Jay Bhattacharya as the next NIH director. The committee votes will set the stage for the full Senate to vote on confirming both nominees later this month. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Acadia, Bloom, Cantargia, Celon, Clarity, Irlab, Lygenesis, Persica. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: ALX, Atara, Axsome, Hikma, TC Biopharm. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Antengene, Bioxodes, Genentech. Read More
